Observational Study of Elizaria® in aHUS Patients

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

April 30, 2022

Conditions
Atypical Hemolytic Uremic SyndromeaHUS
Interventions
DRUG

Elizaria®

Induction cycle: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 1200 mg (4 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 1200 mg every 14 days.

Trial Locations (8)

107014

"State budgetary healthcare institution of the city of Moscow Children's City Clinical Hospital of St. Vladimir of the Healthcare Department of the City of Moscow", Moscow

119991

"Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Health of the Russian Federation", Moscow

123182

"State budgetary healthcare institution of the City of Moscow City clinical hospital #52 of the Moscow City Healthcare Department", Moscow

129327

"State budgetary healthcare institution of the city of Moscow City Clinical Hospital n.a. A.K. Eramishantsev of the Moscow City Healthcare Department", Moscow

191104

"St. Petersburg's State Budgetary Healthcare Institution City Mariinsky Hospital", Saint Petersburg

198205

"St. Petersburg's State Budgetary Healthcare Institution Children's City Multidisciplinary Clinical Specialized Center of High Medical Technologies", Saint Petersburg

420012

"Federal State Budgetary Educational Institution of Higher Education Kazan State Medical University of the Ministry of Health of the Russian Federation", Kazan'

660074

"Regional State Budgetary Healthcare Institution Krasnoyarsk' Regional Clinical Center for Maternity and Childhood Protection", Krasnoyarsk

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY

NCT04749810 - Observational Study of Elizaria® in aHUS Patients | Biotech Hunter | Biotech Hunter